Disrupting the Oncogenic Synergism between Nucleolin and Ras Results in Cell Growth Inhibition and Cell Death

Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras

(2011) K. Farin et al.   CANCER RESEARCH

A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism

(2010) E. M. Reyes-Reyes et al.   CANCER RESEARCH

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

(2010) Nicolas Charette et al.   Molecular Cancer

Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer

(2009) Paula J. Bates et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Structure-Function Analysis of Nucleolin and ErbB Receptors Interactions

(2009) Keren Farin et al.   PLoS One

Nuclear translocation of urokinase-type plasminogen activator

(2008) V. Stepanova et al.   BLOOD

Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin

(2008) Damien Destouches et al.   PLoS One

Identification of Nucleolin as New ErbB Receptors- Interacting Protein

(2008) Ayelet Di Segni et al.   PLoS One